Berlin Cures 完成了 BC 007（Rovunaptabin）第二阶段长期 COVID 试验的患者筛查。 Berlin Cures completes patient screening for Phase II Long COVID trial of BC 007 (Rovunaptabin).

生物科技公司 Berlin Cures 已完成 BC 007（Rovunaptabin）用于长期 COVID 治疗的泛欧洲 II 期试验的患者筛选。 Berlin Cures, a biotech company, has completed patient screening for its pan-European Phase II trial of BC 007 (Rovunaptabin) for Long COVID treatment. 该试验已在欧洲 14 个试验中心招募了 114 名患者，预计将于 2024 年秋季获得首批结果。 The trial has enrolled 114 patients across 14 trial centers in Europe, and first results are anticipated by autumn 2024. 试验正在按计划进行，标志着该公司在帮助数百万长期 COVID 患者方面迈出了重要一步。 The trial progresses on schedule, marking a significant step forward in the company's pursuit to help millions of Long COVID patients.